A recent research finding adds to evidence that brain inflammation is a major driver of neurodegenerative disorders such as ...

R136S, or the “Christchurch mutation,” appears to protect against Alzheimer’s disease by suppressing inflammatory signaling ...

An investigational gene therapy, dubbed scAAV9/JeT-GAN, for a rare neurodegenerative disease, giant axonal neuropathy (GAN), that begins in early childhood was well tolerated and showed signs of ...

A study reveals that the APOE3-R136S mutation delays Alzheimer’s disease by inhibiting the cGAS-STING immune pathway. This ...

Following the report of Phase 1/2 data for the GAN gene therapy last year, Astellas said it would not exercise its option on that program. A key Rett study is ongoing and the option for this ...

In GAN, a gene mutation causes you to have much less of a certain substance in your cells. This substance naturally breaks down protein filaments in your nerves so that the nerves can function ...

An investigational gene therapy for a rare neurodegenerative disease that begins in early childhood, known as giant axonal neuropathy (GAN), was well tolerated and showed signs of therapeutic benefit ...

An investigational gene therapy for a rare neurodegenerative disease that begins in early childhood, known as giant axonal neuropathy (GAN), was well tolerated and showed signs of therapeutic ...

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center show for the first time that a gene usually linked to giant axonal neuropathy, a rare and severe neurological condition, also ...

GAN is caused by mutations in the gene that codes for gigaxonin, a protein important to neuron function. Mutated versions of that protein lead the axons on neurons to become abnormally large and ...

An investigational gene therapy for a rare neurodegenerative disease that begins in early childhood, known as giant axonal neuropathy (GAN), was well tolerated and showed signs of therapeutic ...